WINNIPEG, Manitoba, Jan. 18, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0)
(the "Company" or "3DS"), announces that it has granted 253,125 incentive stock options (the “Options”) to Jason Flowerday, CEO and
Director of 3DS, at an exercise price of $0.79 per share on January 17, 2017.
The Options are exercisable for a ten-year period from the date of grant and will vest in four tranches of
63,281 each every six months from October 1, 2017 to April 1, 2019.
After giving effect to this option grant, a total of 5,121,081 stock options will be issued and outstanding with
151,702 remaining for future issuance under the Company’s stock option plan.
The Options are granted pursuant to the Company’s stock option plan, which was most recently approved by the
shareholders of the Company at the annual general meeting of shareholders held on February 29, 2016.
About 3DS
3DS (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform
based on the three-dimensional analysis chromosomal signatures. The technology is well developed and supported by 16 clinical
studies on over 1,500 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, the
technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is
designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the
Company’s new website at http://www.3dsignatures.com.
Forward-Looking Information
This news release includes forward-looking statements that are subject to risks and uncertainties.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of
the Company to be materially different from the historical results or from any future results expressed or implied by such
forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward
looking. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable
assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from
those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the
results expressed or implied by forward-looking information include, among other things: market demand; technological changes
that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products;
competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental
legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial
condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party
claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical
trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no
assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such
uncertainties. We do not assume any obligation to update any forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Stephen Kilmer Investor Relations 647-872-4849 stephen@kilmerlucas.com OR Hugh Rogers VP Corporate Finance 604-250-6162 investors@3dsignatures.com
